Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Total Current Liabilities (2020 - 2025)

Rapid Micro Biosystems' Total Current Liabilities history spans 6 years, with the latest figure at $16.5 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 3.94% year-over-year to $16.5 million; the TTM value through Sep 2025 reached $16.5 million, up 3.94%, while the annual FY2024 figure was $17.6 million, 7.48% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $16.5 million at Rapid Micro Biosystems, up from $16.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $19.0 million in Q4 2022 and bottomed at $12.8 million in Q2 2022.
  • The 5-year median for Total Current Liabilities is $16.0 million (2021), against an average of $16.1 million.
  • The largest annual shift saw Total Current Liabilities grew 16.86% in 2021 before it fell 20.34% in 2022.
  • A 5-year view of Total Current Liabilities shows it stood at $18.2 million in 2021, then rose by 4.87% to $19.0 million in 2022, then dropped by 0.34% to $19.0 million in 2023, then decreased by 7.48% to $17.6 million in 2024, then dropped by 5.8% to $16.5 million in 2025.
  • Per Business Quant, the three most recent readings for RPID's Total Current Liabilities are $16.5 million (Q3 2025), $16.4 million (Q2 2025), and $15.0 million (Q1 2025).